Description
Cinnarizin Sofarma (Cinnarizinum) Tablets 25 mg. №50
Ingredients:
Each tablet contains 25 mg of Cinnarizinum as the active ingredient.
Mechanism of Action:
Cinnarizinum acts as a calcium channel blocker with antihistaminic properties, contributing to the management of vertigo and motion sickness. Its impact on the vestibular system helps reduce the severity and frequency of vertigo episodes.
Pharmacological Properties:
Cinnarizinum exhibits calcium channel blocking and antihistaminic actions, making it effective in treating vertigo, Meniere’s disease, and motion sickness.
Indications for Use:
Cinnarizinum is indicated for the treatment of vertigo, Meniere’s disease, and motion sickness.
Contraindications:
Avoid using Cinnarizinum if you have a known allergy to cinnarizine or any other components present in the tablets.
Side Effects:
Common side effects may include drowsiness, dry mouth, and gastrointestinal disturbances. If you experience any severe side effects, contact your healthcare provider immediately.
Usage Instructions:
The typical adult dosage is 25 mg (1 tablet) three times daily. Swallow the tablets whole with a glass of water; do not crush or chew them.
Benefits Compared to Analogues:
Cinnarizinum stands out for its efficacy in managing vestibular disorders like vertigo and motion sickness while maintaining a favorable safety profile with minimal adverse effects, making it a preferred choice for patients.
Suitable Patient Groups:
Cinnarizinum can be used in various patient populations, including adults, children (under medical supervision), and the elderly. Dosage adjustments may be necessary based on individual health conditions.
Storage Conditions and Shelf Life:
Store Cinnarizinum tablets in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use the product after the specified shelf life.
Packaging Description:
Cinnarizinum tablets are packaged in a container with 50 tablets, each containing 25 mg of the active ingredient. The packaging is designed to maintain the product’s integrity and ensure proper dosage administration.
Scientific Evidence:
Clinical studies have demonstrated the efficacy of cinnarizine in reducing the severity and frequency of vertigo episodes by its action on the vestibular system. Its calcium channel blocking properties play a crucial role in managing vestibular disorders.
